Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.

Abstract

BACKGROUND:

Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin.

METHODS:

We conducted a post hoc analysis of the ATLAS studies (ClinicalTrials.gov identifiers NCT00091819 and NCT00107978) to explore the efficacy of telavancin in patients with various types of cSSSIs.

RESULTS:

A total of 1794 patients were included in this analysis; 1434 patients were clinically evaluable (CE) and 563 of these had methicillin-resistant Staphylococcus aureus (MRSA). Among CE patients with major abscesses (n = 619), cure rates were 91% for telavancin and 90% for vancomycin (95% CI for the difference -3.6 to 5.7). In patients with infective cellulitis (n = 519), cure was achieved in 87% and 88% of telavancin- and vancomycin-treated patients, respectively (95% CI for the difference -6.2 to 5.2). Cure rates in patients with wound infections were 85% in the telavancin group and 86% in the vancomycin group (95% CI for the difference -10.5 to 9.0). Cure rates for each type of cSSSI in patients infected with MRSA were also similar between the two treatment arms. Among CE patients infected with Panton-Valentine leucocidin (PVL)-positive MRSA (n = 447), cure rates were 93% for telavancin and 90% for vancomycin (95% CI for the difference -2.2 to 8.2).

CONCLUSIONS:

Cure rates were similar for telavancin and vancomycin in patients with different types of cSSSIs, including infections caused by MRSA and PVL-positive strains of MRSA.

• Authors: Martin E Stryjewski, Steven L Barriere, William O'Riordan, Lala M Dunbar, Alan Hopkins, Fredric C Genter, G Ralph Corey
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 67 Issue 6 Pg. 1496-502 (Jun 2012) ISSN: 1460-2091 [Electronic] England
• PMID: 22416054 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)

Chemical References

• Aminoglycosides
• Anti-Bacterial Agents
• Bacterial Toxins
• Exotoxins
• Leukocidins
• Lipoglycopeptides
• Panton-Valentine leukocidin
• Virulence Factors
• telavancin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Aminoglycosides (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Bacterial Toxins (genetics)
• Exotoxins (genetics)
• Female
• Humans
• Leukocidins (genetics)
• Lipoglycopeptides
• Male
• Methicillin-Resistant Staphylococcus aureus (drug effects, isolation & purification)
• Middle Aged
• Randomized Controlled Trials as Topic
• Staphylococcal Skin Infections (drug therapy)
• Treatment Outcome
• United States
• Virulence Factors (genetics)
• Young Adult